Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

33 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer.
Bartsch R, Wenzel C, Gampenrieder SP, Pluschnig U, Altorjai G, Rudas M, Mader RM, Dubsky P, Rottenfusser A, Gnant M, Zielinski CC, Steger GG. Bartsch R, et al. Cancer Chemother Pharmacol. 2008 Oct;62(5):903-10. doi: 10.1007/s00280-008-0682-1. Epub 2008 Feb 7. Cancer Chemother Pharmacol. 2008. PMID: 18256835
Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).
Steger GG, Greil R, Lang A, Rudas M, Fitzal F, Mlineritsch B, Hartmann BL, Bartsch R, Melbinger E, Hubalek M, Stoeger H, Dubsky P, Ressler S, Petzer AL, Singer CF, Muss C, Jakesz R, Gampenrieder SP, Zielinski CC, Fesl C, Gnant M; Austrian Breast and Colorectal Study Group (ABCSG). Steger GG, et al. Ann Oncol. 2014 Feb;25(2):366-71. doi: 10.1093/annonc/mdt508. Epub 2013 Dec 16. Ann Oncol. 2014. PMID: 24347519 Clinical Trial.
Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP, Hufnagl C, Brechelmacher S, Huemer F, Hackl H, Rinnerthaler G, Romeder F, Monzo Fuentes C, Morre P, Hauser-Kronberger C, Mlineritsch B, Greil R. Gampenrieder SP, et al. Pharmacogenomics J. 2017 Jul;17(4):344-350. doi: 10.1038/tpj.2016.25. Epub 2016 May 3. Pharmacogenomics J. 2017. PMID: 27139155
CDK4/6 inhibition in luminal breast cancer.
Gampenrieder SP, Rinnerthaler G, Greil R. Gampenrieder SP, et al. Memo. 2016;9:76-81. doi: 10.1007/s12254-016-0268-2. Epub 2016 Jun 20. Memo. 2016. PMID: 27429659 Free PMC article. Review.
33 results
Jump to page
Feedback